IDEAYA reports 33% ORR in Phase 1 IDE397 in MTAP-deletion urothelial cancer and NSCLC

IDEAYA Biosciences, Inc.

Overall response rate 33% (1 CR, 8 PR) in 27 evaluable patients; all 9 responses confirmed.
Confirmed ORR by tumor: 40% (4/10) urothelial, 38% (3/8) squamous NSCLC, 22% (2/9) adenocarcinoma NSCLC.
Disease control rate 93%; median treatment duration >6.2 months; 15 of 27 patients still on treatment.
ctDNA molecular response rate 81% (≥50% reduction) and 33% (≥90% reduction) in 21 reportable patients.
Favorable safety: 18% Grade 3+ drug-related AEs; no drug-related SAEs or discontinuations; IDE397 + Trodelvy combo to start Q4 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.